Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Filgotinib Progress At Higher Dose Justifies Gilead's Gamble

May 25 2016

• By Eleanor Malone

Rheumatoid-Arthritis-Hands_1200

Related Content

Did Money Motivate AbbVie's Galapagos Decision?

Sep 26 2015

Related Companies

Galapagos NV

Gilead Sciences, Inc.

AbbVie Inc.

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

Eli Lilly and Company

Incyte Corporation

Additional Topics

Clinical Trials Immune Disorders Inflammation

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.